Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1312 clinical trials
Study of AMG 650 in Adult Participants With Advanced Solid Tumors

To evaluate the safety and tolerability of AMG 650 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

  • 0 views
  • 16 Feb, 2024
  • 3 locations
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients …

cancer
squamous cell carcinoma of head and neck
non-small cell lung cancer
hepatocellular carcinoma
urothelial carcinoma
  • 0 views
  • 16 Feb, 2024
  • 4 locations
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) and maximum tolerated dose (MTD) of JNJ-70218902 in Part 1, and to determine the safety of JNJ-70218902 RP2D(s) in Part 2.

castration-resistant prostate cancer
solid neoplasm
adenocarcinoma
gnrh
targeted therapy
  • 0 views
  • 16 Feb, 2024
  • 7 locations
A Study of SBT6050 in Patients With Advanced HER2 Expressing Solid Tumors

A first-in-human (FIH) study using SBT6050 in HER2 expressing advanced malignancies

cancer
pembrolizumab
measurable disease
solid tumor
solid tumour
  • 0 views
  • 16 Feb, 2024
  • 3 locations
Phase Study of the HS-10241 in Patients With Advanced Solid Tumors

HS-10241 is a highly potent and selective small molecule inhibitor of c-Met kinase. In preclinical studies, it demonstrated strong activity against c-Met kinase in vitro and in vivo, and inhibited tumor cell growth. This study is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to …

cancer
solid neoplasm
hysterectomy
carcinoma
ct scan
  • 0 views
  • 05 Aug, 2020
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

The primary objective of the study was to assess investigate the pharmacokinetic effects of Apatinib Mesylate on CYP2C8 Substrate Repaglinide or CYP2B6 Substrate Bupropion and metabolite Hydroxy bupropion in Advanced solid tumor subjects. The secondary objective of the study was to assess the safety of Apatinib or/and Repaglinide and Bupropion.

bupropion
mitomycin
apatinib
targeted therapy
advanced solid tumor
  • 0 views
  • 16 Feb, 2024
  • 1 location
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Approximately 100 adult participants with locally advanced, recurrent, or metastatic solid tumors will be enrolled.

solid neoplasm
measurable disease
ejection fraction
  • 0 views
  • 16 Feb, 2024
  • 2 locations
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

This is an open label Phase 1, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody. It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic, colon and lung cancers.

cancer
solid neoplasm
HER2
measurable disease
ovarian cancer
  • 0 views
  • 05 Aug, 2020
A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid Tumors

The primary objective is to determine the safety profile of SH3051 in subjects with advanced solid tumors. The second objective is to evaluate the PK profile and preliminary efficacy of SH3051 solid tumors.

cancer
aptt
liver metastasis
carcinoma
measurable disease
  • 0 views
  • 05 Aug, 2020
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1 Antibodies

small cell lung cancer
advanced solid tumor
growth factor
ros1
measurable disease
  • 0 views
  • 16 Feb, 2024
  • 8 locations